Aterian Inc vs AstraZeneca plc — how do they compare? Aterian Inc trades at $0.49 (market cap $5.32M), while AstraZeneca plc trades at $158.4 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 46642.9× Aterian Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| ATER | AZN | |
|---|---|---|
Market Cap | $5.32M | $248.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $209.48 |
52-Week Low | $0.36 | $147.06 |
Enterprise Value | $5.90M | $275.41B |
Dividend Yield | — | 2.01% |
Signals from Pluang's Aura AI — not financial advice
ATER trades at $0.47, down 2.56% today, with a bearish technical signal despite recent earnings beats. The company shows deteriorating fundamentals with revenue declining from $221M in 2022 to $69M in 2025 and negative net margins. However, positive developments include a pending asset sale expected to return $0.85-$1.14 per share to stockholders, with proxy advisors recommending approval.
The stock faces significant fundamental challenges with persistent losses and negative cash flow, but the proposed asset sale provides potential near-term catalyst. Analyst sentiment is divided with 50% buy ratings. Key risks include execution of the asset sale and ongoing operational losses, while the technical picture remains bearish near-term.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →